Corporate Overview

We are a clinical stage biopharmaceutical drug development company focused on novel therapeutics targeting currently untreatable eye diseases involving retinal degeneration such as atrophic age-related macular degeneration (commonly known as dry AMD) and autosomal recessive Stargardt disease, or STGD1, both of  which progressively lead to permanent blindness.

We believe our lead product candidate, LBS-008, or Tinlarebant, if approved, would provide a novel treatment option where there currently is none. LBS-008 is an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A (retinol) to the eye as a means to reduce the accumulation of toxic vitamin A by-products in ocular tissue. In clinical trials, LBS-008 has demonstrated its target specificity and potency that we believe could be clinically meaningful to treat STGD1 patients. 

We have initiated an open-label, dose-finding Phase 1b/2 clinical trial in adolescent STGD1 patients in Australia and Taiwan. And we have initiated our Phase 3 clinical trial, to evaluate the safety and efficacy of LBS-008 in adolescent STGD1 patients.


Data Provided by Refinitiv. Minimum 15 minutes delayed.

Upcoming Events

More events are coming soon.

Join our mailing list.


Sign up to receive important updates and news from Belite Bio